6533b828fe1ef96bd1287870
RESEARCH PRODUCT
6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer
Tommy FornanderAnna L.v. JohanssonLj EssermanAdina IftimiBo NordenskjöldChristopher C. BenzChristina YauLinda S. LindströmOlle StålGizeh Pérez-tenorioHuma DarA. Nordensköljdsubject
Oncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicineHER2 negativemedicineTamoxifen therapyHematologyLymph node negativemedicine.diseasebusinessyear | journal | country | edition | language |
---|---|---|---|---|
2021-05-01 | Annals of Oncology |